Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or - Refractory Ovarian Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10333782" target="_blank" >RIV/00064165:_____/16:10333782 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10333782
Result on the web
<a href="http://dx.doi.org/10.1200/JCO.2016.67.1891" target="_blank" >http://dx.doi.org/10.1200/JCO.2016.67.1891</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1200/JCO.2016.67.1891" target="_blank" >10.1200/JCO.2016.67.1891</a>
Alternative languages
Result language
angličtina
Original language name
Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or - Refractory Ovarian Cancer
Original language description
Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key secondary objective was to determine if any of five prespecified biomarkers predicted benefit from seribantumab.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FK - Gynaecology and obstetrics
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Clinical Oncology
ISSN
0732-183X
e-ISSN
—
Volume of the periodical
34
Issue of the periodical within the volume
36
Country of publishing house
US - UNITED STATES
Number of pages
14
Pages from-to
4345-4353
UT code for WoS article
000391380500009
EID of the result in the Scopus database
2-s2.0-85009816442